Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ELAVL4 antisense RNA 1 (ELAVL4-AS1)
- Target
- ELAVL4-AS1
- Molecular classification
- Other (long non-coding RNA, antisense RNA)
01
Overview
ELAVL4 antisense RNA 1 (ELAVL4-AS1) is a long non-coding RNA transcribed antisense to the ELAVL4 locus. While antisense RNAs can regulate their sense counterparts through mechanisms such as RNA-RNA interaction or chromatin modulation, there is no direct evidence in the biomedical literature for a specific functional role, disease association, or druggability of ELAVL4-AS1. In contrast, the protein-coding gene ELAVL4 (HuD) is a well-studied neuronal RNA-binding protein implicated in neurodevelopment, axonal growth, synaptic plasticity, and neurodegenerative diseases such as ALS and Parkinson’s disease[1][3][4]. ELAVL4-AS1 remains poorly characterized and is not recognized as a canonical therapeutic target.
- Other names
- ELAVL4-AS1ELAVL4 antisense RNA 1Antisense non-coding RNA at ELAVL4 locus
02
Mechanism of action
Not applicable; no drugs are documented to act via ELAVL4-AS1
03
Biological functions
Potential gene regulation (by antisense interaction with ELAVL4)No direct functional annotations for ELAVL4-AS1; functions may be inferred or remain unknown
04
Disease associations
No specific associations for ELAVL4-AS1 documented in disease; all disease roles are related to ELAVL4 (HuD), including neurodegeneration and cancerNo evidence for direct involvement of ELAVL4-AS1 in any disease
05
Safety considerations
None described for ELAVL4-AS1
06
Interacting drugs
None known for ELAVL4-AS1
07
Biomarkers
None established specifically for ELAVL4-AS1
Beyond the preview
Go deeper on ELAVL4 antisense RNA 1 (ELAVL4-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELAVL4 antisense RNA 1 (ELAVL4-AS1).